KYMR · Kymera Therapeutics, Inc. · Documents

Feb 27

Current report 8-K

Financial results, Director or officer change, or executive pay

Feb 27

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $47.07M ▼ 40.1% Net loss $223.86M Diluted EPS -$2.98

Jan 14

Current report 8-K

Financial results, Regulation FD disclosure, Other events

Oct 31

Earnings call

Q3 2024 earnings call

Oct 31

Current report 8-K

Financial results

Oct 31

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $3.74M ▼ 20.9% Net loss $62.49M Diluted EPS -$0.82

Oct 31

Registration statement S-3ASR

Registration statement

Aug 20

Current report 8-K Events of Aug 19

Entered into a material agreement, Other events

Aug 7

Earnings call

Q2 2024 earnings call

Aug 7

Current report 8-K

Financial results

Aug 7

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $25.65M ▲ 55.3% Net loss $42.06M Diluted EPS -$0.58

Jul 8

Current report 8-K

Regulation FD disclosure, Other events

Jun 20

Current report 8-K Events of Jun 18

Director or officer change, or executive pay, Shareholder vote results

May 2

Earnings call

Q1 2024 earnings call

May 2

Current report 8-K

Financial results

May 2

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $10.29M ▲ 8.7% Net loss $48.56M Diluted EPS -$0.69

Apr 24

Proxy statement DEF 14A Meeting Jun 18, 2024

Proxy statement

Apr 24

Annual report to holders ARS

Annual report to holders

Apr 24

Proxy statement DEFA14A

Proxy statement

Apr 1

Current report 8-K Events of Mar 28

Director or officer change, or executive pay

Feb 22

Earnings call

Q4 2023 earnings call

Feb 22

Current report 8-K

Financial results

Feb 22

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $78.59M ▲ 67.8% Net loss $146.96M Diluted EPS -$2.52

Jan 5

Current report 8-K Events of Jan 4

Entered into a material agreement, Financial results, Other events

Jan 4

Current report 8-K

Regulation FD disclosure, Other events

Jan 4

Current report 8-K

Regulation FD disclosure

Nov 2

Current report 8-K

Financial results

Nov 2

Earnings call

Q3 2023 earnings call

Nov 2

Current report 8-K

Regulation FD disclosure, Other events

Nov 2

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $4.73M ▼ 50.5% Net loss $52.87M Diluted EPS -$0.90

Aug 3

Earnings call

Q2 2023 earnings call

Aug 3

Current report 8-K

Financial results

Aug 3

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $16.51M ▲ 43.4% Net loss $38.8M Diluted EPS -$0.67

Jun 16

Current report 8-K Events of Jun 15

Shareholder vote results

May 22

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

May 4

Earnings call

Q1 2023 earnings call

May 4

Current report 8-K

Financial results

May 4

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $9.47M ▼ 1.6% Net loss $40.93M Diluted EPS -$0.70

Apr 27

Proxy statement DEF 14A

Proxy statement

Apr 27

Annual report to holders ARS

Annual report to holders

Apr 27

Proxy statement DEFA14A

Proxy statement

Mar 10

Current report 8-K

Regulation FD disclosure

Feb 27

Current report 8-K

Director or officer change, or executive pay

Feb 23

Current report 8-K

Financial results

Feb 23

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $46.83M ▼ 35.7% Net loss $154.81M Diluted EPS -$2.87

Jan 10

Earnings call

Q4 2022 earnings call

Jan 10

Current report 8-K

Financial results

Dec 14

Current report 8-K

Regulation FD disclosure, Other events

Dec 14

Current report 8-K

Regulation FD disclosure

Nov 3

Earnings call

Q3 2022 earnings call